Medicines Co. rises on Angiomax drug settlement - Forbes.com

NEW YORK -- Shares of The Medicines Co. climbed Monday after the company settled a patent infringement lawsuit on its anti-clotting drug Angiomax, which brings in nearly all of the company's revenue. THE SPARK: The Parsippany, N.J., company said Monday it ended a lawsuit against Teva Pharmaceutical Industries Ltd. (TEVA - news - people ), which was seeking approval to market a generic version of Angiomax.